Introduction: Vancomycin Resistant Enterococci (VRE) is fast emerging pathogen causes serious & life threatening hospital borne infections. The limitation in therapeutic options has resulted in the development of new drugs such as Quinupristin/ Dalfopristin, Linezolid & Tigecycline.
Introduction
The enterococci have emerged as major causes of nosocomial infections, recognized as the 3rd most common cause of bacteremia. This increase in infection is due in part to resistance to standard therapies, such as high level aminoglycosides and the betalactam antimicrobial agents-and more recently, to the glycopeptides, including vancomycin and teicoplanin. VRE can remain viable in the environment for an extended time period, and therefore poise a problem for infection control in hospitals and nursing homes. In addition, these enterococci have been detected as part of the enteric flora in non-symptomatic patients. These colonized patients serve as potential sources for transfer of this organism to other patients and medical personnel. Enterococci are primarily opportunistic pathogens. Progress in medical technology and intensive use of broad spectrum antibiotics in the hospitals had been responsible for emergence of these organisms as important nosocomial pathogens [1] . Though the major problem in treatment of VRE infection arises in endocarditis, the urinary tract is the commonest site from where bacteraemia can occur. There are very few reports on isolation of VRE from India [2] . It is not always easy to assess the clinical significance of VRE in routine culture or to differentiate colonisation from infection. Therefore, the pre-sent study was undertaken to look for vancomycin resistance in enterococci obtained in significant numbers from various clinical samples at a tertiary care centre, Ahmedabad, Gujarat, Western India.
Epidemiology
During the 1960s and 1970s, it was seen that gram negative organisms were leading causes of hospital acquired infections. Gram-positive organisms were typically sensitive to most antibiotics. However, with the emergence of gram-positive organisms as leading causes of hospital acquired infection in the 1990s, called for a re-evaluation of public research priorities. One of the organisms that caused concern was Vancomycin Resistant Enterococcus (VRE) that was first reported in France in 1988 [3] . Since then, the incidences of Vancomycin Resistant Enterococcus have been reported in many parts of the world. The number of cases infected with VRE, as reported by the US Centers for Disease Control and Prevention, has risen from 99 in 1992 to 278 in 1994. The more recent reports are both distressing as well as alarming. Studies propose that prolonged hospital stay and the irrational use of vancomycin were important risk factors for both vancomycinresistances in Enterococci. Other significant factors that were associated with the emergence of vancomycin-resistant Enterococci were renal dialysis and or renal failure, prior aminoglycoside and the use of third generation cephalosporins. It also emphasized on the importance of screening for VRE in clinical samples. Vancomycin resistant Enterococcus is known to cause significant mortality and morbidity [4] . Enterococcus, or vancomycin-resistant enterococci (VRE), are bacterial strains of the genus Enterococcus that are resistant to the antibiotic vancomycin. 
Materials and Methods
From July 2010 to July 2011, as per table-1, a total of 250 enterococcal isolates -81 from urine, 91 from blood, 27 from wound swabs, 18 from pus and 33 from fluids (ascitic fluid 6, cerebrospinal fluid 17 and peritoneal dialysis fluid 2 and pleural fluid 8) were processed. Identification of isolates up to the species level was done by standard biochemical tests according to the conventional scheme of Facklam and Collins [6] . Screening for Vancomycin resistance was done by agar screen methods [7] on Mueller-Hinton agar (MHA). Antibiotic sensitivity was carried out by Kirby Bauer disc diffusion test [8] as per CLSI guidelines. Susceptibility to Vancomycin was performed by using 30µg disc. Minimum Inhibitory Concentration (MIC) of all the isolates were done by Vancomycin Ezy MIC TM Strip ranging from 0.016 µg/ml to 256 µg/ml. Plates were incubated at 35ºC for 24 hours. Susceptibility to high level Gentamicin by using 120 µg disc, Penicillin by 10 unit disc and Teicoplanin by using 30µg disc were also performed. Enterococcus faecalis ATCC 29212 and Enterococcus faecalis ATCC 51299 (Vancomycin resistant strain) were used as control strain. The records of the patients whose samples grew VRE in significant numbers were reviewed for demography, clinical findings, underlying medical problems, surgical procedures, invasive devices, and treatment with antimicrobial agents and outcome.
Results
Out of the 250 Enterococcus species, 58% (145) were Enterococcus faecalis and 42% (105) were Enterococcus faecium. 10 isolates were resistant to Vancomycin disc, giving an overall VRE positivity of 4%. Out of 10 VRE, 40% (4) were isolated from urine, 40% (4) from blood and 20% (2) (7) were resistant to Vancomycin by MIC according to CLSI guidelines. In this study, among 10 VRE isolates, 80% (8) were E. faecium and 20% (2) were E. faecalis. 23.60% (59) out of 250 isolates were resistant to high level Gentamicin and all VRE were high level aminoglycoside resistants. [9] . VRE may inhabit a host and cause no discernable problem that is called colonization. VRE infections may be difficult to cure because the bacteria do not respond to many antibiotics. Sometimes more than one antibiotic is prescribed to help stop the infection. Part of treatment protocol may include sending samples of your blood, urine, or stool to a lab to see if you still have VRE in your body. VRE infection can occur throughout the body with the most common body sites being the urinary tract, surgical wounds, and/or bloodstream [10] .
Recently, a phenotypic classification system was devised to categorize the VRE into three groups: vanA strains, which show highlevel Vancomycin resistance (minimum inhibitory concentrations [MIC] of >32 mcg per ml) and resistance to Teicoplanin; vanB strains, which have variable resistance to Vancomycin (MICs of 4 to >128 mcg per ml) and susceptibility to Teicoplanin; and vanC strains, which show intrinsic resistance to low-levels of Vancomycin (MICs of 2 to l6 mcg per ml) and susceptibility to Teicoplanin. It is important for the laboratorian to distinguish these strains from the other enterococci which show high-level Vancomycin resistance, since the former are not considered an epidemiological threat for nosocomial transfer and are usually susceptible susceptible to standard therapies. A major reason for the survival of Enterococcus in hospital environment is their intrinsic resistance to several commonly used antibiotics and, perhaps more important, their ability to acquire resistance to all currently available antibiotics, either by mutation or through the transfer of plasmids and transposons [11] . While Enterococcus is inherently resistant to most of the drugs, Vancomycin resistance complicates treatment and management of the disease. The prognosis is also affected leading to increased mortality and morbidity [12] . The other factors that are also affected are the added burden on costs incurred by the patient in the form of prolonged hospital stay and medication. [14] .
There is no vaccine to protect against VRE. The most important infection control measure is wash hands before eating, drinking, applying personal care products, and after using the toilet. Bacteria can survive on surfaces like railings, faucets and handles for up to seven days. Routine cleaning of these surfaces with regular household cleaners can also help reduce spread of bacteria. Visitors need to follow hospital guidelines to prevent the spread of VRE. This includes washing hands or using alcohol hand rub when entering and leaving the hospital and/or the patient room. Precautions shall be taken to protect other patients and hospital staff from VRE infection.
Conclusion
Guidelines have been established by CDC to prevent the spread of Vancomycin resistance. Each hospital needs to be familiar with the guidelines for the prevention of Vancomycin resistance and establish a policy that reflects their unique needs. The principle recommendations advocated are: 1) the prudent use of Vancomycin; 2) An ongoing education program for all hospital staff about the threat of VRE; 3) A cooperative effort between health care providers and hospital microbiology laboratory personnel that will allow VRE to be promptly and accurately detected; and, 4) The implementation of appropriate infection-control measures to prevent person-to-person spread of VRE;5) screening of health care workers in order to identify carrier rates 6) surveillance cultures in high prevalence areas such as intensive care units and operation 
